Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome
- PMID: 28655598
- DOI: 10.1016/j.clml.2017.05.017
Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome
Abstract
Background: Management of mycosis fungoides and Sézary syndrome (MF/SS) is complex, and randomized evidence to guide treatment is lacking. The institutional treatment volumes for MF/SS might vary widely nationally and influence patient survival.
Patients and methods: Using the National Cancer Database, we identified patients with a diagnosis of MF/SS from 2004 to 2011 in the United States who had received treatment at a reporting facility. The patients were grouped into quintiles according to their treatment facility's average annual treatment volume (ATV). The characteristics associated with ATV were identified and compared using χ2 tests. Overall survival (OS) was compared among the ATV quintiles using the Kaplan-Meier method with log-rank tests and multivariable Cox regression with hazard ratios (HRs). OS was also analyzed using the annual patient volume as a continuous variable.
Results: A total of 2205 patients treated at 374 facilities were included for analysis. The ATV quintile cutoffs were 1, 3, 6, and 9 patients. With a median follow-up period of 59 months, the 5-year estimated OS survival increased with ATV from 56.7% in the lowest quintile (≤ 1 patient annually) to 83.8% in the highest quintile (> 9 patients annually; P < .001). On multivariable analysis, greater ATV was associated with improved survival when analyzed as a continuous variable (HR, 0.96 per patient per year; 95% confidence interval, 0.94-0.98; P < .001) and when comparing the highest quintile to the lowest quintile (HR, 0.46; 95% confidence interval, 0.39-0.55).
Conclusion: The present national database analysis demonstrated that higher facility ATV is associated with improved OS for patients with MF/SS. Further study is needed to determine the underlying reasons for improved survival with higher facility ATV.
Keywords: Cutaneous T-cell lymphoma; Facility volume; MF; National Cancer Database; SS.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e105-12. doi: 10.1016/j.clml.2015.02.027. Epub 2015 Mar 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25817937
-
Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.Turk J Haematol. 2018 Mar 1;35(1):35-41. doi: 10.4274/tjh.2016.0502. Epub 2017 May 23. Turk J Haematol. 2018. PMID: 28533196 Free PMC article.
-
Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.JAMA Dermatol. 2014 Jul;150(7):709-15. doi: 10.1001/jamadermatol.2013.7747. JAMA Dermatol. 2014. PMID: 24718769
-
Mycosis Fungoides and Sézary Syndrome: An Update.Hematol Oncol Clin North Am. 2019 Feb;33(1):103-120. doi: 10.1016/j.hoc.2018.09.001. Hematol Oncol Clin North Am. 2019. PMID: 30497668 Free PMC article. Review.
-
Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.Curr Treat Options Oncol. 2021 Jan 7;22(2):10. doi: 10.1007/s11864-020-00809-w. Curr Treat Options Oncol. 2021. PMID: 33415447 Review.
Cited by
-
A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)-A Retrospective Cohort Study.Front Med (Lausanne). 2021 Jul 2;8:679294. doi: 10.3389/fmed.2021.679294. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34277658 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials